RANI Archives - BioTuesdays

Executive Moves

Rani appoints Dr. Alireza Javadi as CTO

Rani Therapeutics (NASDAQ: RANI) has announced the promotion of Alireza Javadi, PhD, to chief technical officer. Prior to the promotion to CTO, Dr. Javadi served as Rani’s VP, technical operations, where he was...

January 28, 2026

Developments

Rani posts successful drug delivery of high-capacity pill

Rani Therapeutics Holdings (NASDAQ:RANI) reported three new positive preclinical studies that support development of a high-capacity oral biologics device, known as the RaniPill HC, a version of the RaniPill capsule...

September 8, 2023

Developments

Rani posts positive repeat-dose results with RaniPill in osteoporosis

Rani Therapeutics (NASDAQ:RANI) reported topline results from the repeat-dose Part 2 of a Phase 1 study of RT-102, the RaniPill GO capsule containing a proprietary formulation of human parathyroid hormone being...

December 7, 2022

Developments

Rani Therapeutics posts positive Phase 1 results in osteoporosis

Rani Therapeutics (NASDAQ:RANI) reported positive topline results from the single-ascending dose portion of its Phase 1 clinical study of RT-102, a RaniPill capsule containing a proprietary formulation of human...

August 11, 2022

Developments

Rani’s RaniPill wins Fast Company’s 2022 World Changing Ideas Award

Rani Therapeutics (NASDAQ:RANI) took top honors for its RaniPill capsule in the health category of Fast Company‘s 2022 World Changing Ideas. The RaniPill capsule is about the size of a standard fish oil pill...

May 3, 2022

Feature

Rani developing technology for oral delivery of injectable biologics

Rani Therapeutics (NASDAQ:RANI) is developing a disruptive technology to solve the problem of converting biologic injectable drugs, including antibodies, peptides and proteins, into oral therapies with its RaniPill that...

December 7, 2021

Markets

Analysts start Rani Therapeutics at buy; PT $24

Analysts for Stifel and BTIG launched coverage of Rani Therapeutics (NASDAQ:RANI) with “buy” ratings and price targets of $24, respectively. The stock closed at $17.76 on Aug. 24. “Rani appears to have cracked the...

August 25, 2021

Tag - RANI

Rani appoints Dr. Alireza Javadi as CTO

Rani posts successful drug delivery of high-capacity pill

Rani posts positive repeat-dose results with RaniPill in osteoporosis

Rani Therapeutics posts positive Phase 1 results in osteoporosis

Rani’s RaniPill wins Fast Company’s 2022 World Changing Ideas Award

Rani developing technology for oral delivery of injectable biologics

Analysts start Rani Therapeutics at buy; PT $24

Subscribe